FDA Approves 2nd Blood CRC Test
Freenome's SimpleScreen CRC cleared FDA on July 27 with 81.1% cancer sensitivity and 90.4% specificity - but the approval only solves half the problem when 45 million Americans still won't show up for a colonoscopy follow-up.
Colorectal cancer will kill more than 55,000 Americans this year. Ninety percent of those deaths are preventable. And roughly 45 to 48 million eligible adults are currently overdue for screening - a number that climbs toward 60 million when you add those due for rescreening.
On July 27, 2026, the FDA approved SimpleScreen CRC, Freenome's blood-based screening test for colorectal cancer in adults 45 and older at average risk. Abbott will exclusively commercialize it in the U.S. this fall. This is the second blood-based primary CRC screening test approved by the FDA, joining Guardant Health's Shield, which was approved in 2024.
The test is a genuine breakthrough. A simple blood draw. No bowel prep. No sedation. No need to arrange transportation home. But the approval is only half the equation. The other half - what happens when the test returns a positive result - is where most health systems and FQHCs are not ready.
1. What the FDA Actually Approved
The PREEMPT CRC pivotal study is the largest prospective clinical validation ever conducted for a blood-based CRC screening test. It enrolled more than 48,000 asymptomatic, average-risk adults aged 45 to 85 across more than 200 sites. The results that drove FDA approval:
📊 CRC sensitivity: 81.1% - meaning SimpleScreen correctly identified about 8 in 10 colorectal cancers.
📊 Specificity for advanced colorectal neoplasia: 90.4% - correctly producing negative results in 9 of 10 people without CRC or advanced precancerous lesions.
📊 Sensitivity for advanced precancerous lesions: 13.7% overall, rising to 30.7% for those with high-grade dysplasia.
In adults aged 45 to 49 - the group added to screening guidelines in 2021 and historically hardest to reach - SimpleScreen showed 100% sensitivity for CRC and 94.8% specificity for advanced colorectal neoplasia.
The test meets Medicare coverage criteria. That is a critical structural advantage. It removes the single largest access barrier for the population most likely to skip colonoscopy: Medicare-age patients in underserved communities who already face transportation burdens, time constraints, and procedure anxiety.
The American Cancer Society has also already incorporated SimpleScreen CRC into its updated colorectal cancer screening guidelines by name. That clinical endorsement matters for health system procurement decisions, and for the payer conversations that follow.
2. The Screening Gap Is Structural, Not Clinical
The FDA approval fixes a technology problem that was never actually the core problem. The core problem is structural.
Only 63.5% of adults aged 45 to 75 are up to date with colorectal cancer screening nationally. In FQHCs - where 43 million patients receive care, many of them uninsured or underinsured - that rate drops to 43%. The national goal is 80%.
📊 Among uninsured adults aged 45 to 64: only 23.8% are screened - compared to 64.7% of those with private insurance.
📊 69% of U.S. counties have no gastroenterologist. More than half of practicing gastroenterologists are age 55 or older.
These numbers tell you something important: the barrier to colonoscopy was never primarily the procedure itself. It was the infrastructure required to access the procedure. A blood draw at a routine visit removes the symptom. But it does not remove the systemic cause.
For FQHC administrators, the math is different than for large health systems. An FQHC that starts ordering SimpleScreen CRC at scale will generate positive results it has to act on. A positive SimpleScreen result triggers a diagnostic colonoscopy referral. If the FQHC does not have a defined referral pathway, a patient navigator assigned to the follow-up, and a mechanism to track colonoscopy completion in its population health dashboard - the test creates a new bottleneck without closing the old gap.
The same dynamic played out with Cologuard and stool-based DNA testing. Health systems deployed the test widely. Positive result follow-through rates at under-resourced sites were far lower than at integrated systems. The test worked. The infrastructure did not.
3. Abbott's Market Play
Abbott's exclusive commercialization deal for SimpleScreen CRC is not a side note. It is the story.
Abbott is one of four companies that control the majority of U.S. outpatient laboratory market share. Its commercial infrastructure - established lab accounts, managed care contracting relationships, hospital system agreements, and outpatient clinic reach - gives SimpleScreen CRC an immediate distribution advantage that Freenome alone could not have built.
📊 Abbott's diagnostics division generated $6.7 billion in revenue in 2025.
📊 The colorectal cancer blood-based screening market is projected to exceed $3 billion annually by 2030 as blood-based testing displaces lower-adherence alternatives.
Guardant Health commercializes Shield independently, with a focused direct-to-provider sales model. Abbott enters with an established salesforce, payer contracts, and laboratory partnerships already in place. That means SimpleScreen CRC can reach community clinics, FQHCs, and rural health centers that Shield's more specialized salesforce has not yet fully penetrated.
For health system administrators, this translates into a meaningful procurement reality: Abbott can negotiate multi-test lab bundles, integrate SimpleScreen into existing lab draw workflows, and in many cases reduce friction compared to adding a new vendor relationship.
4. How SimpleScreen Compares to Existing Modalities
SimpleScreen CRC enters a market that already has a crowded modality landscape. Understanding where it fits - and where it does not - is essential for health system procurement decisions.
📊 Colonoscopy remains the gold standard. It is both diagnostic and therapeutic. A colonoscopy can find and remove a polyp in a single procedure. No blood test can do that.
📊 Stool-based DNA tests (Cologuard) have 92.3% sensitivity for CRC but only 86.6% specificity. The higher false positive rate drives more confirmatory colonoscopies.
📊 FIT (fecal immunochemical test) is inexpensive and widely deployed but requires annual testing and has lower sensitivity (79% for CRC at single use).
📊 SimpleScreen CRC: 81.1% sensitivity, 90.4% specificity, once every three years, blood draw only.
The three-year testing interval is a meaningful advantage for adherence. Colonoscopy is recommended every ten years. FIT annually. Cologuard every one to three years. A test patients only have to do every three years, at a routine blood draw, has a higher ceiling for adherence compliance than any stool-based alternative.
5. The Next-Generation Signal
In July 2026 - the same month the original SimpleScreen CRC received FDA approval - Freenome reported top-line results from its pivotal clinical validation study for a next-generation SimpleScreen CRC test. All primary and secondary endpoints were met.
Freenome has announced it will submit a supplemental Premarket Approval (PMA) to the FDA for this updated version. The next-gen test is expected to show improved sensitivity for advanced precancerous lesions - the area where the current test has its lowest performance (13.7%).
This is the clinical gap that matters most for population health. A test that catches cancer at a high rate but misses most advanced precancerous lesions is a meaningful tool but not a complete screening program. Colonoscopy remains necessary for that layer of detection.
The next-gen submission matters for three reasons. First, improved lesion sensitivity could support a longer testing interval or reduce confirmatory colonoscopy volume. Second, the regulatory pathway is already established - a supplemental PMA rather than a new application. Third, ACS guideline updates typically follow significant performance improvements in FDA-cleared tests.
📊 The current test: 13.7% sensitivity for advanced precancerous lesions.
📊 The next-gen study: met all primary and secondary endpoints - exact numbers pending publication.
6. What FQHCs Need to Build Before Ordering
The FQHC context requires a different implementation framework than a large integrated health system. FQHCs serve patients who are more likely to face transportation barriers, more likely to be uninsured or Medicaid-dependent, and less likely to have a PCP relationship that enables proactive follow-up.
For FQHC administrators, the question is not whether to add SimpleScreen CRC to the formulary. The question is whether the follow-up infrastructure is in place to act on a positive result before the first test is ordered.
Pre-Launch Checklist for FQHC Administrators
Three operational questions need answers before deployment:
First: Do you have a defined follow-up protocol for positive results with a specific time-to-action target? A positive SimpleScreen CRC result without a colonoscopy referral pathway is a liability, not a service.
Second: Who owns the patient navigation for colonoscopy follow-up? At most FQHCs, this falls to the care team with no dedicated resource. If you deploy the test at scale, you need a navigation protocol before the results start coming back.
Third: How will you track screening completion - not just test ordering - in your population health dashboard? The meaningful metric is colonoscopy completion after a positive blood test. That number is what determines whether this test saves lives in your patient population.
📊 FQHC CRC screening rates: 43% nationally, vs. 80% national goal.
📊 Patient navigation interventions in FQHCs increase colonoscopy follow-through after a positive non-invasive test by 30 to 50 percentage points in published studies.
The blood draw is the easy part. The hard part is the system design that happens after the result comes back.
Deep Dive
The Financial Model for Blood-Based CRC Screening at an FQHC
The economics of SimpleScreen CRC adoption look different depending on your payer mix and current screening infrastructure.
For an FQHC serving a predominantly Medicare panel, SimpleScreen CRC is cost-neutral to order under current Medicare coverage guidance. The downstream costs are in the confirmatory colonoscopy pathway. Approximately 10% of patients who take SimpleScreen CRC will receive a positive result (based on the 9.6% false positive rate for advanced colorectal neoplasia). Of those, a meaningful percentage will be true positives requiring colonoscopy.
For a mid-size FQHC with 5,000 age-eligible patients:
📊 Tests ordered (assuming 70% uptake over 3 years): 3,500 tests
📊 Estimated positive results: 350 (10% positive rate)
📊 True positive cancers identified: 28 (based on 81.1% sensitivity applied to population prevalence of roughly 1%)
📊 True positive advanced lesions identified: 48 (based on 13.7% sensitivity applied to 10% advanced neoplasia prevalence)
📊 Confirmatory colonoscopies needed: 350
📊 Cost of colonoscopy referral per patient (including navigation): $800 to $1,400 depending on facility and insurance coverage
The business case for FQHCs is not the test cost. It is the infrastructure investment in navigation and follow-up. FQHCs that build that infrastructure capture the downstream colonoscopy referral value and the prevention benefit. FQHCs that do not build it generate positive results they cannot act on.
The Equity Gap Blood Tests Can and Cannot Close
Blood-based CRC screening can close the access gap for patients who refuse colonoscopy. It cannot close the equity gap created by systemic underinvestment in follow-up infrastructure.
The most underscreened populations in the U.S. are Black Americans, Hispanic Americans, and low-income adults - the same populations FQHCs disproportionately serve. Black Americans are 20% more likely to develop CRC and 40% more likely to die from it compared to white Americans. The blood draw removes one barrier. It does not remove lack of paid time off, lack of transportation for a colonoscopy appointment, or language barriers in the colonoscopy referral process.
The equity case for SimpleScreen CRC is real. Blood draws happen at routine visits. They require no special scheduling, no prep, no escort. For patients who have never screened because colonoscopy felt impossible, a blood draw at an existing appointment is a genuine on-ramp.
But the equity case is only as strong as the follow-up infrastructure. A positive result that does not generate a completed colonoscopy is, clinically, worse than no test at all - because the patient now carries an unresolved finding with no clear next step.
What This Means For You
FQHC executives and community health center leaders: Do not order the test before the follow-up pathway exists. Define your colonoscopy referral protocol, assign patient navigation responsibility, and establish a completion metric in your population health dashboard. The test works. The infrastructure is your responsibility.
Health system administrators and CMOs: Evaluate Abbott's existing lab relationships before adding Freenome as a new vendor. If Abbott is already in your lab network, SimpleScreen CRC may reduce procurement friction versus Shield. The ACS guideline inclusion means payer coverage conversations will move faster than with Shield in its first year.
Radiologists and pulmonologists: Blood-based CRC screening reduces colonoscopy volume in the population that was never going to comply anyway - the 45 million overdue patients. It does not reduce colonoscopy volume in your panel. The confirmatory colonoscopy after a positive blood test is a diagnostic study, not a screening study, and drives higher acuity referrals.
Healthcare investors and founders: The blood-based CRC market is now a two-player primary screening market: Shield and SimpleScreen CRC. The differentiation story will shift from clinical performance (both tests are comparable) to distribution scale and follow-up navigation software. The company that builds the best positive-result-to-colonoscopy-completion workflow wins the enterprise contract.
Policy advocates: The 43% FQHC screening rate versus the 80% national goal is a policy failure, not a technology failure. Blood-based tests improve access. Sustained CHC Fund investment, patient navigation reimbursement, and gastroenterology capacity-building in underserved markets are the policy levers that determine whether the approval changes the mortality curve.
The FDA approval of SimpleScreen CRC is genuinely important news. The 55,000 Americans who will die of colorectal cancer this year - most of them preventable deaths - needed a better tool. They now have two blood-based options.
The question for every health system and FQHC leader is the same: now that the tool exists, what will you build around it?
A blood test that generates a positive result and no follow-up did not save a life. It created a liability. The work starts after the draw.
If you lead a health system, FQHC, or policy organization working on this issue, reply to this post. The infrastructure problem is solvable. It just requires the same deliberate attention that the FDA approval received.
About the Author
Jonathan Govette is the Co-Founder and CEO of Oatmeal Health, an AI lung cancer diagnostic company catching cancers earlier in the communities that need it most. Oatmeal uses AI to identify unscreened high-risk patients, navigate them to care, and score every lung CT for malignancy risk - billed under CPT 0721T. Stage I survival is 77%. Stage IV is 9%. We work in FQHCs because that gap is largest there.
Jonathan writes daily about radiology, pulmonology, AI diagnostics, health policy, hospital operations, and healthcare startups.
Subscribe to stay ahead of healthcare's most important shifts. Weekly deep-dives on AI, radiology, health policy, FQHCs, and the business of healthcare - written for operators, clinicians, and investors who want the signal, not the noise. Subscribe at oatmealhealthjonathangovette.substack.com
Key References
Freenome press release: FDA Approves Freenome's SimpleScreen CRC Blood-Based Screening Test - https://www.freenome.com/newsroom/fda-approves-freenomes-simplescreen-crc/ (July 27, 2026)
Colorectal cancer statistics 2026 - PMC/NIH: 158,850 new CRC cases projected in 2026 - https://pmc.ncbi.nlm.nih.gov/articles/PMC12951547/
FQHC CRC screening rates (43% vs. 80% goal) - NIH PMC study on organizational factors - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12932028/
Guardant Shield FDA approval and Medicare coverage framework (2024) - https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Healths-Shield-Blood-Test-Approved-by-FDA-as-a-Primary-Screening-Option-Clearing-Path-for-Medicare-Reimbursement-and-a-New-Era-of-Colorectal-Cancer-Screening/default.aspx
Forbes - Millions Are Overdue For Colon Cancer Screening (Feb 2026) - https://www.forbes.com/sites/adairalandry/2026/02/25/millions-are-overdue-for-colon-cancer-screening-cologuard-can-help/